A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Recruiting

Phase 1

PF-07934040 with Anti-cancer TherapiesA Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Sponsor:

Pfizer

Code:

NCT06447662

Conditions

Carcinoma, Pancreatic Ductal

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PF-07934040

Gemcitabine

Nab-paclitaxel

Cetuximab

Fluorouracil

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Pfizer on 2025-04-16.